New combo pill shows promise for HIV patients fighting TB
NCT ID NCT04734652
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 32 times
Summary
This study tested a new HIV medication (Biktarvy) taken twice daily in 122 adults with both HIV and tuberculosis (TB). Participants were already on standard TB treatment. The goal was to see if the new pill could control HIV as well as the current standard treatment. Results showed it was effective at suppressing the virus through 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CAPRISA Springfield Clinical Research Site
Durban, KwaZulu-Natal, 4001, South Africa
Conditions
Explore the condition pages connected to this study.